PDCD1 and neoplasm: In melanoma-bearing mouse models, butyrate supplementation with anti-PD-1 therapy significantly reduced tumor volume and increased the percentage of IFN-γ+ and tumor necrosis factor (TNF)-α+ cells among tumor infiltrating CD4+ and CD8+ T cells.